Process-Based Approach Case Series For Anxiety Problems (PBT)

May 27, 2026 updated by: Nicholas C. Borgogna, University of Alabama at Birmingham
A case series of PBA intervention for anxiety problems.

Study Overview

Status

Not yet recruiting

Conditions

Intervention / Treatment

Detailed Description

Participants will self-refer to this study by emailing a research assistant (Mr. Whittington).

They will then attend a screening session where they complete an informed consent form and are assessed for inclusion/exclusion criteria. During the screening the research assistant will conduct a clinical interview and collaboratively identify hypothetical processes (e.g. avoidance) that might be contributing to the participants anxiety symptoms. Together, they will identify 8-items from the process-based assessment tool (see survey) that might be relevant to the participants anxiety.

Participants will then complete a baseline survey battery on a lab computer (via Qualtrics; ~20 minutes).

Participants will then complete a two-week assessment period where they complete brief (<2 minute) surveys five times a day (approximately 9 am, noon, 2 pm, 5 pm, and 8 pm) each day for the two weeks. These surveys will be sent to participants' phone via Qualtrics. These surveys will be the 8-items identified during the intake session, with one additional item assessing momentary anxiety and an additional item assessed momentary quality of life perception.

The research team will use the data gathered during the two-week assessment period to create personalized networks of processes leading to participant anxiety symptoms. Each participants' network will guide their therapy treatment.

Participants will then attend up to 25 sessions of counseling for their anxiety. Sessions will occur roughly weekly and will last approximately 50 minutes. All sessions will occur in Dr. Borgogna's lab and clinic space (Campbell Hall Ste 310) on the UAB campus. The therapists in the study will all be masters-level clinicians in the UAB medical/clinical psychology program preparing for licensure (Mr. Whittington, Mr. Johnson, and Ms. Jafari) or a licensed clinical psychologist (Dr. Borgogna). Therapy sessions for pre-licensed clinicians will be recorded onto a UAB computer in Dr. Borgogna's lab and reviewed for supervision purposes by Dr. Borgogna (A/V recordings not for research purposes). Recordings will be deleted within 30 days of each therapy session.

Participants will complete the main battery again at post-test.

Study Type

Interventional

Enrollment (Estimated)

10

Phase

  • Not Applicable

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Contact

  • Name: Damion D Whittinton, MS
  • Phone Number: (205) 934-3850
  • Email: whitdrew@uab.edu

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

  • Adult
  • Older Adult

Accepts Healthy Volunteers

Yes

Description

Inclusion Criteria:

  • Score on GAD-7 >10 at baseline
  • Access to mobile device

Exclusion Criteria:

  • Current psychotherapy treatment
  • Current/past severe psychopathology (e.g., history of psychosis, suicide attempt or self-injury within the past 12 months, narcotics use within the past 3 months)

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: Treatment
  • Allocation: N/A
  • Interventional Model: Single Group Assignment
  • Masking: None (Open Label)

Arms and Interventions

Participant Group / Arm
Intervention / Treatment
Experimental: Process-based approach
PBA therapy
Process-Based Approaches (PBA) were developed to improve psychotherapy outcomes. Early writings referred to PBA as process-based therapy or process-based cognitive behavioral therapy. The current nomenclature was adopted to distinguish PBA as a unifying approach that incrementally builds on clinical psychological science rather than a manualized treatment protocol. PBA provides a framework for flexibly applying evidence-based techniques from multiple therapeutic traditions to target hypothesized psychological processes that give rise to individual patient presentations. Each patient is conceptualized independently, and intervention structure may vary substantially based on need, while retaining empirically supported tools. This contrasts with disorder-specific treatment manuals, which assume homogeneity despite substantial variability in underlying processes (e.g., anxiety).
Other Names:
  • PBT

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Generalized Anxiety Disorder-7
Time Frame: From enrollment to the end of treatment, up to 25 weeks.
Anxiety scale
From enrollment to the end of treatment, up to 25 weeks.
Beck Anxiety Inventory
Time Frame: From enrollment to the end of treatment, up to 25 weeks.
Anxiety Measure
From enrollment to the end of treatment, up to 25 weeks.

Secondary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Patient Health Questionnaire-9
Time Frame: From enrollment to the end of treatment, up to 25 weeks.
Depression measure
From enrollment to the end of treatment, up to 25 weeks.
Experiential Avoidance Rating Scale
Time Frame: From enrollment to the end of treatment, up to 25 weeks.
Experiential avoidance measure
From enrollment to the end of treatment, up to 25 weeks.
Quality of Life Scale
Time Frame: From enrollment to the end of treatment, up to 25 weeks.
Quality of Life Measure
From enrollment to the end of treatment, up to 25 weeks.
Big Five Inventory
Time Frame: From enrollment to the end of treatment, up to 25 weeks.
Measure of Personality
From enrollment to the end of treatment, up to 25 weeks.
PSY-Flex
Time Frame: From enrollment to the end of treatment, up to 25 weeks.
Psychological flexibility measure
From enrollment to the end of treatment, up to 25 weeks.

Other Outcome Measures

Outcome Measure
Measure Description
Time Frame
Process-based assessment tool
Time Frame: Five times a day for two weeks prior to intervention
A collection of hypothetical processes that might be correlated with mental illness outcomes. Selections will be used to inform patient conceptualizations prior to therapy.
Five times a day for two weeks prior to intervention

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Investigators

  • Principal Investigator: Nicholas C Borgogna, PhD, University of Alabama at Birmingham

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Estimated)

May 1, 2026

Primary Completion (Estimated)

December 31, 2027

Study Completion (Estimated)

December 31, 2027

Study Registration Dates

First Submitted

January 9, 2026

First Submitted That Met QC Criteria

January 9, 2026

First Posted (Actual)

January 20, 2026

Study Record Updates

Last Update Posted (Actual)

May 28, 2026

Last Update Submitted That Met QC Criteria

May 27, 2026

Last Verified

May 1, 2026

More Information

Terms related to this study

Additional Relevant MeSH Terms

Other Study ID Numbers

  • UAB PBT

Plan for Individual participant data (IPD)

Plan to Share Individual Participant Data (IPD)?

YES

IPD Plan Description

De-identified outcome scores will be shared in publication. Raw scores are available upon request to the principal investigator.

IPD Sharing Time Frame

2027-2030

IPD Sharing Access Criteria

PhD-level researchers associated with academic institutions will have access to de-identified spreadsheets and code.

IPD Sharing Supporting Information Type

  • STUDY_PROTOCOL
  • ICF
  • ANALYTIC_CODE

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Anxiety

Clinical Trials on Process-Based Approach

Subscribe